Skip to main content
. 2018 Nov 29;13:8063–8074. doi: 10.2147/IJN.S186881

Figure 3.

Figure 3

Drug distribution in tissues (A) and plasma (B) for Olaparib at 1, 3, 6, 24, 48, and 72 hours following intraperitoneal injection of NanoOlaparib.

Note: All data followed a normal distribution as tested by the Shapiro–Wilk test.

Abbreviation: GI, gastrointestinal.